secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001711279-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M
--------------------------------------------------------------------------------

- Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).
- Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.
- Cash, cash eq & investments $749.6M as of Dec 31, 2024.
- Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.
- FY2025 non-GAAP R&D+SG&A guidance $150-175M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/0001711279-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/krys-20250219.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer